The FDA approved Bioguard is a non-leaching antimicrobial dressing and had its first commercial sale of the product in June 2009. The dressings serve as a barrier to infection, kill germs absorbed into the dressing, and do not interfere with tissue healing.
The company has claimed that the dressing’s active agent maintains effectiveness even in the presence of large amounts of proteinaceous exudates. The technology within Bioguard dressings is protected by nine US patents and patents pending and 24 foreign counterparts.
Ed Quilty, CEO of Derma Sciences, said: “Our initial sales, along with our recently announced Acute Care distribution agreement with Medline Industries, position us well to maximize sales of this important dressing. The expanded term and scope of the agreement will help to make this brand a key contributor to our overall success for years to come.”
Ladd Greeno, CEO of Quick-Med, said: “Quick-Med is excited to enter into this amended license agreement with Derma Sciences. Derma has successfully demonstrated its ability to quickly commercialise our proprietary Nimbus technology and the expanded grant of rights provides them with important additional products.”